Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas
BsAbs represent a major advance in B-NHL, offering high rates of deep remission with predictable safety and outpatient feasibility. As trial data continues to mature, BsAb-based regimens are poised to become foundational across multiple lines of therapy, reshaping expectations for patients with both aggressive and indolent lymphomas.
Authors
- Aditi Saha (ORCID: https://orcid.org/0000-0003-3421-3971)
- Khushali Jhaveri (ORCID: https://orcid.org/0000-0002-0232-3896)
- Julio C. Chávez (ORCID: https://orcid.org/0000-0002-2045-6238)
- Luis Miguel Juárez‐Salcedo (ORCID: https://orcid.org/0000-0003-1448-8601)
Institutions
- University of Alabama at Birmingham Hospital (US)
- University of Alabama (US)
- Jacksonville College (US)
- WinnMed (US)
- University of Alabama at Birmingham (US)
- Hospital Universitario de La Princesa (ES)
- Mayo Clinic in Florida (US)
- University School (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Indiana University (US)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/14712598.2025.2597847
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00